1 40 1 Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Treatment of Symptoms in Children with Q3 Conditions Scoping Review Results Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. URL Address <a href="http://doi.org/10.1002/mds.25126" target="_blank" rel="noreferrer noopener">http://doi.org/​10.1002/mds.25126</a> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource A randomized trial of oral betamethasone to reduce ataxia symptoms in ataxia telangiectasia Publisher An entity responsible for making the resource available Movement Disorders Date A point or period of time associated with an event in the lifecycle of the resource 2012 Subject The topic of the resource tone and motor problems; ataxia; ataxia telangectasia; pharmacologic intervention; betamethasone; Creator An entity primarily responsible for making the resource Zannolli R; Buoni S; Betti G; Salvucci S; Plebani A; Soresina A; Pietrogrande M C; Martino S; Leuzzi V; Finocchi A; Micheli R; Rossi L N; Brusco A; Misiani F; Fois A; Hayek J; Kelly C; Chessa L Description An account of the resource No controlled studies exist regarding the pharmaceutical reduction of ataxia symptoms in ataxia telangiectasia (A-T). In a multicenter, double-blind, randomized, placebo-controlled crossover trial, oral betamethasone (BETA) and placebo were compared in terms of their reduction of ataxia symptoms as assessed with the International Cooperative Ataxia Rating Scale (ICARS). In this study of 13 A-T children, betamethasone reduced the ICARS total score by a median of 13 points in the intent-to-treat population and 16 points in the per-protocol population (ie, median percent decreases of ataxia symptoms of 28% and 31%, respectively). In conclusion, Oral betamethasone could be a promising therapy to relieve ataxia symptoms in A-T patients; however, long-term effectiveness and safety must be established. (Current Controlled Trials, number ISRCTN08774933). © 2012 Movement Disorder Society. Identifier An unambiguous reference to the resource within a given context <a href="http://doi.org/10.1002/mds.25126" target="_blank" rel="noreferrer noopener">10.1002/mds.25126</a> Rights Information about rights held in and over the resource Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s). 2012 ataxia ataxia telangectasia betamethasone Betti G Brusco A Buoni S Chessa L Finocchi A Fois A Hayek J Kelly C Leuzzi V Martino S Micheli R Misiani F Movement Disorders pharmacologic intervention Pietrogrande M C Plebani A Rossi L N Salvucci S Soresina A tone and motor problems Zannolli R